Reaxys Announces Winners of the 2013 Reaxys PhD Prize
NEUCHÂTEL, Switzerland, July 3, 2013 /PRNewswire/ –
The Reaxys PhD Prize awards original and innovative research in organic,
organometallic and inorganic chemistry
(R), a unique workflow solution for
chemistry research, has today announced the winners of the 2013 Reaxys PhD Prize
[http://inspiringchemistry.reaxys.com/phdprize ]. Awarding innovative and original
research in organic, organometallic and inorganic chemistry, the Reaxys PhD Prize
celebrates top research conducted by leading young chemists across the globe.
The 2013 Reaxys PhD Prize Winners are:
- Martin Donakowski from the Poeppelmeier group at Northwestern University, USA - Max Hansmann from the Hashmi group at University of Heidelberg, Germany - Johannes Heppekausen from the Fuerstner group at the Max-Planck Institute, Muelheim, Germany
The winners were selected from 45 finalists by the Chairs of the Reaxys PhD Prize’s
review board: Professors Tony Barrett (Imperial College London, UK), Eiichi Nakamura
(University of Tokyo, Japan), Gerard Parkin (Columbia University, New York, USA), Martin
Jansen (Max-Planck Institute, Stuttgart, Germany), Barry Trost (Stanford University, USA)
and Henry Wong (Chinese University Hong Kong, Hong Kong).
“Since its inception in 2010 there has been an ever increasing number of superb
applications for the Reaxys PhD Prize. Whilst this has provided the review board with an
immense task of selecting the top three candidates, their efforts have been rewarded by
the delight of reading such elegant creative synthetic chemistry,” said Professor Barrett.
“There is no doubt that the future global strength of chemistry is securely based on a
cohort of outstanding young scientists, who are all a credit to our subject and to their
own universities. I look forward to personally interacting with members of the Reaxys
Prize Club, a most select society.”
This year a record of 581 submissions were received from nearly 400 universities
across the globe. Submissions consisted of a representative, peer-reviewed published
research paper accompanied by a PhD’s supervisor recommendation letter and CV. Entries
were closely scrutinized by a review board of over 100 international chemists from
academia and industry. The reviewers judged the entries for originality, innovation,
importance to the field, applicability, rigor of approach and publication quality.
The three winners and 42 remaining finalists have been invited to attend the Reaxys
Inspiring Chemistry Conference [http://inspiringchemistry.reaxys.com/conference ] which
will be held in Grindelwald, Switzerland, September 22 – 24, 2013 where they will be given
the opportunity to present their research.
For more information about the Reaxys PhD Prize and Chemistry Conference go to:
For more information about Reaxys go to http://www.elsevier.com/reaxys
Reaxys(R) is a workflow solution for research chemists. Offering a wealth of
experimentally validated information, Reaxys(R) combines reaction and substance data in
organic, organometallic, inorganic and physical chemistry with synthesis planning.
Researchers can get the information they need in a single overview, from source
publications carefully selected for their importance and relevance to research chemists.
Elsevier continues to engage with the chemistry community to ensure that Reaxys(R)
continues to reflect how chemists think and work. For more information please visit Reaxys
Reaxys(R) and the Reaxys(R) trademark are owned and protected by Reed Elsevier
Properties SA and used under license.
About Reed Elsevier Properties SA
Reed Elsevier Properties SA is a centre of excellence within Reed Elsevier for the
management, development and protection of intellectual property. Reed Elsevier Properties
SA owns the PharmaPendium and Reaxys databases. Trademarks including Reaxys(R),
PharmaPendium(R), Targetinsights(TM), The Lancet(R) and World Travel Market(R) are owned
and protected by Reed Elsevier Properties SA and used under licence.
Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier’s online
solutions include ScienceDirect [http://www.sciencedirect.com ], Scopus
[http://www.scopus.com ], Reaxys [http://www.elsevier.com/reaxys ], ClinicalKey
[https://www.clinicalkey.com ] and Mosby’s Suite [http://www.confidenceconnected.com ],
which enhance the productivity of science and health professionals, and the SciVal suite
[http://www.scival.com ] and MEDai’s Pinpoint Review [http://www.medai.com ], which help
research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc
[http://www.reedelsevier.com/Pages/Home.aspx ], a world leading provider of professional
information solutions. The group employs more than 30,000 people, including more than
15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies,
Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam
and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam:
REN; New York: RUK and ENL.
Media contact Liz Griffioen Elsevier +31-20-485-2247 firstname.lastname@example.org